Shares of Edwards Lifesciences Corp. (NYSE:EW) saw an uptick in trading volume on Thursday . 2,287,881 shares traded hands during trading, an increase of 57% from the previous session’s volume of 1,455,487 shares.The stock last traded at $114.95 and had previously closed at $112.71.

A number of research firms have recently commented on EW. Jefferies Group reaffirmed a “buy” rating and issued a $125.00 price target (up from $105.00) on shares of Edwards Lifesciences Corp. in a report on Wednesday, April 27th. Morgan Stanley raised their price target on Edwards Lifesciences Corp. from $110.00 to $140.00 and gave the stock an “overweight” rating in a report on Wednesday, July 27th. Deutsche Bank AG raised their price target on Edwards Lifesciences Corp. from $100.00 to $115.00 and gave the stock a “hold” rating in a report on Wednesday, July 27th. JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $130.00 price target on shares of Edwards Lifesciences Corp. in a report on Thursday, July 28th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $140.00 price target on shares of Edwards Lifesciences Corp. in a report on Thursday. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have given a buy rating to the company’s stock. Edwards Lifesciences Corp. has an average rating of “Buy” and an average price target of $116.10.

The company has a market cap of $24.47 billion and a PE ratio of 47.50. The company has a 50 day moving average price of $109.04 and a 200 day moving average price of $99.02.

Edwards Lifesciences Corp. (NYSE:EW) last announced its earnings results on Tuesday, July 26th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.70 by $0.06. The business had revenue of $759.30 million for the quarter, compared to analysts’ expectations of $724.26 million. During the same quarter in the prior year, the company posted $0.57 earnings per share. The firm’s quarterly revenue was up 23.1% compared to the same quarter last year. Equities analysts predict that Edwards Lifesciences Corp. will post $2.87 earnings per share for the current year.

In other Edwards Lifesciences Corp. news, Director Steven R. Loranger bought 5,000 shares of the firm’s stock in a transaction dated Tuesday, May 24th. The shares were purchased at an average cost of $101.07 per share, for a total transaction of $505,350.00. Following the transaction, the director now owns 1,941 shares of the company’s stock, valued at $196,176.87. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 18,000 shares of the company’s stock in a transaction dated Tuesday, May 31st. The shares were sold at an average price of $99.04, for a total transaction of $1,782,720.00. Following the sale, the vice president now owns 62,796 shares in the company, valued at $6,219,315.84. The disclosure for this sale can be found here.

Several hedge funds have made changes to their positions in EW. Suntrust Banks Inc. boosted its stake in shares of Edwards Lifesciences Corp. by 126.2% in the fourth quarter. Suntrust Banks Inc. now owns 19,421 shares of the medical research company’s stock valued at $1,533,000 after buying an additional 10,835 shares in the last quarter. Spectrum Advisory Services Inc. raised its stake in Edwards Lifesciences Corp. by 103.4% in the fourth quarter. Spectrum Advisory Services Inc. now owns 24,274 shares of the medical research company’s stock worth $1,917,000 after buying an additional 12,337 shares during the period. Eaton Vance Management raised its stake in Edwards Lifesciences Corp. by 100.0% in the fourth quarter. Eaton Vance Management now owns 33,126 shares of the medical research company’s stock worth $2,616,000 after buying an additional 16,563 shares during the period. Utah Retirement Systems raised its stake in Edwards Lifesciences Corp. by 99.0% in the fourth quarter. Utah Retirement Systems now owns 38,536 shares of the medical research company’s stock worth $3,044,000 after buying an additional 19,168 shares during the period. Finally, Autus Asset Management LLC raised its stake in Edwards Lifesciences Corp. by 93.1% in the fourth quarter. Autus Asset Management LLC now owns 57,518 shares of the medical research company’s stock worth $4,543,000 after buying an additional 27,736 shares during the period.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.